From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 16:16 (1547 d 03:39 ago) – Posting: # 20924
Views: 6,288

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,638 registered users;
39 visitors (0 registered, 39 guests [including 8 identified bots]).
Forum time: 19:55 CET (Europe/Vienna)

Exploratory analysis: The art of finding a Rembrandt
in a Jackson Pollock.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5